Sirona Biochem Corp. (V:SBM*CA)

Business Focus: Biotechnology & Medical Research (NEC)

Apr 08, 2024 02:00 am ET
SIRONA BIOCHEM Corporate Update April 2024
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) provides the following update: Dear shareholders, We are pleased to provide an update on our recent milestones and strategic decisions shaping Sirona...
Apr 04, 2024 09:24 pm ET
Sirona Biochem Announces Close of Private Placement
Vancouver, British Columbia – April 4, 2024 – Sirona Biochem Corp. (TSX-V: SBM) (Frankfurt: ZSB) (“Sirona”) has closed its private placement (Private Placement”) for gross proceeds of $132,500 CAD. The Private Placement consists of 1,325,000 units,...
Mar 28, 2024 05:00 pm ET
Sirona Biochem Announces 2023 Annual Meeting Results
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) announces the voting results from its Annual General Meeting of Shareholders (the "Meeting"), held in Vancouver, British Columbia on March 28, 2024. The total number of shares...
Mar 13, 2024 09:00 am ET
Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) announces a significant achievement in its quest to transform the skincare industry. Its subsidiary, TFChem, has successfully received formulations for its...
Feb 21, 2024 09:00 am ET
Sirona Biochem Announces Plans for Commercial Launch of GlycoProteMim™ in Early 2025
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF), also known as Sirona, is excited to share a new milestone in its journey. A recent exclusive video interview featuring Dr. Geraldine Deliencourt-Godefroy, Sirona's Chief Scientific...
Feb 15, 2024 05:50 pm ET
Sirona Biochem Provides Update on Loan
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) announce that, further to its news release on January 29, 2024, it has entered into an amendment to the demand grid promissory note dated September 22, 2023 (the...
Feb 15, 2024 09:00 am ET
Sirona Biochem Engages Global Beauty Consulting
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) has announced its partnership with Global Beauty Consulting – Cosmetics Laboratory (GBC), under the leadership of CEO Gaël Boutry, a distinguished French...
Jan 29, 2024 08:30 am ET
Sirona Biochem Announces Loan
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) announced that it has entered into a demand grid promissory note (the “Note”) with 0906462 B.C. Ltd. (the “Lender”) for a loan in the aggregate principal amount...
Jan 26, 2024 06:07 pm ET
Sirona Biochem Initiates Private Placement
Sirona Biochem Corp. (TSX-V:SBM) (FSE: ZSB) (OTC: SRBCF) (the "Company") is pleased to announce a non-brokered private placement of up to 10,000,000 units of the Company at a price of $0.10 CAD per Unit (a "Unit") for gross proceeds of up to...
Jan 24, 2024 11:14 am ET
CORRECTION -- Sirona Biochem Corporate Update January 2024
In a release issued under the same headline earlier today by Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF), please note that in the 8th paragraph of the letter, the company plans to launch its first product early in the 1st quarter of...
Jan 24, 2024 01:30 am ET
Sirona Biochem Corporate Update January 2024
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) provides the following update: Dear shareholders, We are pleased to provide an update on our recent milestones and strategic decisions shaping...
Jan 15, 2024 01:00 am ET
Sirona Biochem Launches Cosmetics Subsidiary- Sirona Laboratories™
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) is proud to introduce Sirona LaboratoriesTM - a wholly-owned subsidiary dedicated to maximizing the commercial potential of its breakthrough anti-aging skincare ingredient, GlycoProteMimTM....
Dec 11, 2023 09:50 am ET
Sirona Biochem Initiates GlycoProteMim™ Trademark for Anti-Aging Molecule TFC-1326
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF), is making a strategic move in the world of advanced skincare solutions. Today, the company announces the trademarking of its groundbreaking anti-aging and anti-wrinkle molecule, TFC-1326,...
Oct 25, 2023 06:28 pm ET
Sirona Biochem Announces Change of Auditor
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC:SRBCF) (the “Company") announces that it has changed its auditors from DeVisser Gray LLP (the “Former Auditor”) Davidson and Company (the “Successor Auditor”) effective October 25, 2023 and the...
Oct 24, 2023 10:58 pm ET
TSX Venture Exchange Stock Maintenance Bulletins
VANCOUVER, BC, Oct. 24, 2023 /CNW/ -
Oct 20, 2023 04:50 pm ET
Sirona Biochem Announces Payment of Convertible Debenture Interests in Shares
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) announces that pursuant to the 12% unsecured, convertible debentures in the principal amount of $1,500,000 (the “Debentures”) previously issued on April 20, 2023,...
Jul 13, 2023 09:00 am ET
Sirona Biochem Corporate Update
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) provides the following update: Dear shareholders, We are pleased to provide an update on the progress we have made over the last months: Corporate Strategic Planning One of...
Jun 28, 2023 09:00 am ET
Sirona Biochem Advances Antiviral Research with New Compound Candidates for Testing at the ICGEB
June 28, 2023 – Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) ("Sirona") is excited to announce the development of a promising new set of potential antiviral compounds which will undergo testing at the renowned International Centre for...
May 25, 2023 09:00 am ET
Sirona Biochem Engages Atheln Inc. to Strengthen Business Development Initiatives
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) ("Sirona") is pleased to announce it has contracted Atheln Inc. ("Atheln"), a leading US consulting firm, to bolster and facilitate Sirona's business activities. This strategic initiative...
May 11, 2023 09:00 am ET
Sirona Biochem: Investing News Network Interview with CSO, Dr. Geraldine Deliencourt-Godefroy
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona”) is pleased to announce that the Investing News Network has published an exclusive video interview with Dr. Geraldine Deliencourt-Godefroy, the Chief Scientific Officer of...
May 03, 2023 09:00 am ET
Sirona Biochem to Present Ground-breaking Anti-Aging Technology at BIO 2023 Conference in Boston
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTCQB: SRBCF) ("Sirona") is excited to announce that Dr. Geraldine Deliencourt-Godefroy, Chief Scientific Officer, will be presenting the Company's latest anti-aging technology, TFC-1326, at the...
Apr 25, 2023 09:00 am ET
Sirona Biochem Announces Exceptional Clinical Trial Results for Anti-Aging Compound TFC-1326
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to announce that the clinical trial results, for novel anti-aging compound TFC-1326, have exceeded even high expectations on key criteria. The trial, which was...
Apr 20, 2023 04:19 pm ET
Sirona Biochem Announces Close of Oversubscribed Debenture Financing
Sirona Biochem Corp. (TSX-V: SBM) (Frankfurt: ZSB) (Xetra: ZSB) (the “Company”) announced today that it has closed an oversubscribed, non-brokered convertible debenture for gross proceeds of $1,563,600. The private placement consists of 1,563...
Mar 23, 2023 09:00 am ET
Sirona Biochem Announces Debenture Financing
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) is pleased to announce a non-brokered private placement offering of unsecured, convertible debentures (the “Convertible Debentures”). The Company is offering...
Feb 27, 2023 09:00 am ET
Sirona Biochem Receives Antiviral Testing Results
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to announce it has received results from its research collaboration with the International Centre for Genetic Engineering and Biotechnology (“ICGEB”) to advance...
Jan 16, 2023 09:00 am ET
Sirona Biochem Announces the Termination of Supply Agreement with Rodan + Fields
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) announces the termination of the Rodan + Fields (R+F) agreement for supply and use of TFC-1067 in commercial formulations. Allergan Aesthetics, an AbbVie company (NYSE: ABBV),...
Dec 30, 2022 01:22 pm ET
Sirona Biochem Announces 2022 Annual Meeting Results
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) announces the voting results from its Annual General Meeting of Shareholders (the "Meeting"), held in Vancouver, British Columbia on December 30, 2022. The total number of shares...
Dec 08, 2022 09:00 am ET
Sirona Biochem Announces Start of Clinical Trial for Anti-Aging Compound TFC-1326
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to announce that the clinical trial, for novel anti-aging compound TFC-1326, started on December 5th, 2022. The trial, which will take place in Paris, is designed to...
Nov 23, 2022 09:00 am ET
Sirona Biochem Signs International Partnership Agreement with Wanbang Biopharmaceuticals
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) announces that, subsequent to the LOI, Sirona and Wanbang Biopharmaceuticals (“Wanbang”) have signed an expanded, international partnership agreement to collaborate on licencing...
Nov 16, 2022 09:00 am ET
Sirona Biochem Reports Positive Results in Safety Study for Anti-Aging Compound TFC-1326
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to announce positive results of the clinical safety study for their novel anti-aging compound TFC-1326 1% in formulation, now proven to be a non-irritant and...
Nov 10, 2022 03:00 am ET
Sirona Biochem Signs Research Collaboration Agreement with International Centre for Genetic Engineering and Biotechnology
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to announce it has entered into a research collaboration with the International Centre for Genetic Engineering and Biotechnology (“ICGEB”) to advance Sirona’s antiviral...
Sep 28, 2022 10:02 pm ET
Sirona Biochem Issues Corporate Update
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona”) announces the release of a corporate update which highlights the company’s recent team meeting in France, the current pipeline, and the latest deal structure. With the success...
Jul 12, 2022 03:00 am ET
Sirona Biochem Corporate Update
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) provides the following update: Dear shareholders, We are pleased to provide an outlook of our ongoing corporate development. On June 13th we announced that we had successfully...
Jun 22, 2022 03:00 am ET
Sirona Biochem Contracts WuXi AppTec to Manufacture Revolutionary Anti-Aging/Anti-Wrinkle Compound for Clinical Trial
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to announce that it has signed an agreement with Contract Manufacturing Organization (CMO) WuXi AppTec (“WuXi”), Shanghai, for the small-scale production of TFC-1326, a...
Jun 20, 2022 03:00 am ET
Former Bayer Senior Executive Joins Sirona Biochem Advisory Board
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to announce that Dr. Wolfgang Bieber will join Sirona Biochem’s Advisory Board and act as a consultant to the Board of Directors with immediate effect. Dr. Wolfgang...
Jun 15, 2022 08:00 am ET
Sirona Biochem Initiates Significant Corporate Changes
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to inform about several significant corporate changes currently in preparation: Now that Sirona Biochem has closed an exclusive global licencing agreement with...
Jun 13, 2022 08:00 am ET
Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to announce it has entered into a global exclusive licensing agreement with Allergan Aesthetics, an AbbVie company (NYSE: ABBV), pursuant to which Allergan Aesthetics...
Apr 11, 2022 03:00 am ET
Sirona Biochem CEO Quarterly Update
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to provide the following update to shareholders. Dear shareholders, We continue to make fundamental progress on core objectives and will be able to share more in due...
Mar 09, 2022 03:00 am ET
Sirona Biochem Subsidiary, TFChem, Awarded Financing in Partnership with French Government
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona”) is pleased to announce that its wholly owned subsidiary TFChem, has been awarded financing to develop an advanced chemistry process that could improve the manufacturing of...
Jan 18, 2022 03:00 am ET
Sirona Biochem Renews Agreement with CURE Intelligence for Marketing and Communications Support
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona”) is pleased to announce that it has renewed an agreement with Luxembourg-based analytics and marketing specialist CURE Intelligence for marketing intelligence services and...
Jan 12, 2022 03:00 am ET
Sirona Biochem Sponsors Fluorine Chemistry Symposium, Normandy, France
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to announce sponsorship of the French Fluorine Chemistry Symposium which will take place in Normandy, France, May 16-19, 2022 in Forges-les-Eaux...
Jan 04, 2022 03:00 am ET
Sirona Biochem CEO Quarterly Update
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to provide the following update to shareholders. Dear shareholders, We provide this update with conviction that value-driving developments ahead will open a new...
Dec 20, 2021 02:00 am ET
Sirona Biochem Antiviral Compounds to be Tested Against SARS-CoV-2 by Top US Testing Facility
VANCOUVER, BC, Dec. 20, 2021 /CNW/ - Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) (OTC: SRBCF) ("Sirona") announces the advancement of 20 antiviral compounds to In Vitro testing. The compounds will be shipped to the Utah State University's Institute of Antiviral Research for evaluation against the SARS-CoV-2 virus (COVID-19).
Dec 16, 2021 02:00 am ET
Sirona Biochem Announces Engagement of Pullan Consulting to Close Optimal Deal for TFC-1067
VANCOUVER, BC, Dec. 16, 2021 /PRNewswire/ -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) ("Sirona") is very pleased to announce that Linda Pullan of Pullan Consulting will be providing strategic direction with the negotiations and licensing of TFC-1067.
Dec 13, 2021 08:00 am ET
Sirona Biochem Provides Update on SGLT2 Inhibitor for Type 2 Diabetes in China
VANCOUVER, BC, Dec. 13, 2021 /CNW/ - Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) (OTC: SRBCF) ("Sirona") announces that it has received notice that the development of Sirona's SGLT2 inhibitor, TFC-039, will be discontinued by Wanbang Biopharmaceuticals ("Wanbang") as a treatment for type 2 diabetes in China.
Nov 10, 2021 01:48 pm ET
Sirona Biochem Announces 2021 Annual Meeting Results: Shareholders Approve All Resolutions With Majority Vote
VANCOUVER, BC, Nov. 10, 2021 /CNW/ - Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) (OTC: SRBCF)  ("Sirona") is pleased to announce the voting results from its Annual General Meeting of Shareholders (the "Meeting"), held in Vancouver, British Columbia on November 10, 2021. The total number of shares represented by shareholders present in person and by proxy at the meeting was 33,335,079, representing 14.45% of Sirona's issued and outstanding Common Shares.
Oct 12, 2021 09:00 am ET
Oct 12, 2021 03:00 am ET
Sirona Biochem: Investing News Network Interview with CEO, Dr. Howard Verrico
Featuring an update on anticipated deal for TFC-1067
Oct 06, 2021 09:00 am ET
/R E P E A T -- Sirona Biochem Announces Advancement of TFC-1067/
VANCOUVER, BC, Oct. 6, 2021 /CNW/ - Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) (OTC: SRBCF) ("Sirona") is pleased to provide the following Q3 update to shareholders.
Oct 06, 2021 03:00 am ET
Sirona Biochem Announces Advancement of TFC-1067
VANCOUVER, BC, Oct. 6, 2021 /CNW/ - Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) (OTC: SRBCF) ("Sirona") is pleased to provide the following Q3 update to shareholders.
Jun 30, 2021 09:00 am ET
/R E P E A T -- Sirona Biochem CEO Quarterly Update Q2 2021/
VANCOUVER, BC, June 30, 2021 /CNW/ - Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) (OTC: SRBCF) ("Sirona") is pleased to provide the following update to shareholders.
Jun 30, 2021 03:00 am ET
Sirona Biochem CEO Quarterly Update Q2 2021
VANCOUVER, BC, June 30, 2021 /CNW/ - Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) (OTC: SRBCF) ("Sirona") is pleased to provide the following update to shareholders.
Mar 31, 2021 09:00 am ET
/R E P E A T -- Sirona Biochem Reports Excellent Results in New Clinical Study on TFC-1067/
VANCOUVER, BC, March 31, 2021 /CNW/ - Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") is pleased to announce that the second clinical trial of the active ingredient, TFC-1067, has been completed with excellent results.
Mar 31, 2021 03:00 am ET
Sirona Biochem Reports Excellent Results in New Clinical Study on TFC-1067
VANCOUVER, BC, March 31, 2021 /CNW/ - Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") is pleased to announce that the second clinical trial of the active ingredient, TFC-1067, has been completed with excellent results.
Mar 10, 2021 08:00 am ET
/R E P E A T -- Sirona Biochem Announces Launch of First Commercial Product Containing TFC-1067/
VANCOUVER, BC, March 10, 2021 /CNW/ - Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) (US-OTC: SRBCF) is pleased to announce the launch of the first commercial product containing the Company's proprietary ingredient, TFC-1067. TFC-1067 will debut as the active ingredient in New Rodan + Fields REVERSE Targeted Dark Spot Corrector. It will precisely target stubborn discoloration for a brighter, even-looking skin tone.
Mar 10, 2021 02:00 am ET
Sirona Biochem Announces Launch of First Commercial Product Containing TFC-1067
VANCOUVER, BC, March 10, 2021 /CNW/ - Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) (US-OTC: SRBCF) is pleased to announce the launch of the first commercial product containing the Company's proprietary ingredient, TFC-1067. TFC-1067 will debut as the active ingredient in New Rodan + Fields REVERSE Targeted Dark Spot Corrector. It will precisely target stubborn discoloration for a brighter, even-looking skin tone.
Feb 24, 2021 08:00 am ET
/R E P E A T -- Sirona Biochem CEO Quarterly Update Q1 2021/
VANCOUVER, BC, Feb. 24, 2021 /CNW/ - Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) (OTC: SRBCF) ("Sirona") is pleased to provide the following update to shareholders.
Feb 24, 2021 02:00 am ET
Sirona Biochem CEO Quarterly Update Q1 2021
VANCOUVER, BC, Feb. 24, 2021 /CNW/ - Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) (OTC: SRBCF) ("Sirona") is pleased to provide the following update to shareholders.
Feb 03, 2021 05:00 pm ET
Sirona Biochem Announces Grant of Stock Options
VANCOUVER, BC, Feb. 3, 2021 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF)("Sirona" or the "Company") announces that it has granted an aggregate of 350,000 incentive stock options to independent directors and consultants of the Company. The options, to purchase common shares in the capital of the Company at a price of $0.38 per common share, will be for periods ranging from 1 to 5 years. The options have been granted under the terms of the Company's stock option plan.
Dec 15, 2020 05:05 am ET
Sirona Biochem Signs Agreement with Luxembourg-based CURE Intelligence for Social Media and Communications Support
VANCOUVER, BC, Dec. 15, 2020 /CNW/ - Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") is pleased to announce that it has signed an agreement with Luxembourg-based analytics and marketing specialist CURE Intelligence to manage online analytics and social media communication.
Nov 30, 2020 08:00 am ET
/R E P E A T -- Sirona Biochem Releases CEO Letter to Shareholders/
VANCOUVER, BC, Nov. 30, 2020 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") is pleased to provide an update from the Company's CEO, Dr. Howard Verrico.
Nov 30, 2020 02:00 am ET
Sirona Biochem Releases CEO Letter to Shareholders
VANCOUVER, BC, Nov. 30, 2020 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") is pleased to provide an update from the Company's CEO, Dr. Howard Verrico.
Oct 26, 2020 09:00 am ET
/R E P E A T -- Sirona Biochem Announces Acceptance of Clinical Study for TFC-1067 in the Journal of Cosmetic Dermatology/
VANCOUVER, BC, Oct. 26, 2020 /CNW/ - Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) (USOTC: SRBCF) ("Sirona") is pleased to announce that the clinical study using .2% TFC-1067 and conducted by Dr. Zoe Draelos of Dermatology Consulting Services, North Carolina, has been peer reviewed and accepted for publication in the Journal of Cosmetic Dermatology.
Oct 26, 2020 03:00 am ET
Sirona Biochem Announces Acceptance of Clinical Study for TFC-1067 in the Journal of Cosmetic Dermatology
VANCOUVER, BC, Oct. 26, 2020 /CNW/ - Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) (USOTC: SRBCF) ("Sirona") is pleased to announce that the clinical study using .2% TFC-1067 and conducted by Dr. Zoe Draelos of Dermatology Consulting Services, North Carolina, has been peer reviewed and accepted for publication in the Journal of Cosmetic Dermatology.
Oct 13, 2020 09:00 am ET
/R E P E A T -- Sirona Biochem Signs Agreement with Global Pharmaceutical Company for Clinical Trial of its Novel Skincare Compound TFC-1067/
VANCOUVER, BC, Oct. 13, 2020 /CNW/ - Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") is pleased to announce that it has signed an agreement with a top 10 global pharmaceutical company ("Company") to jointly test Sirona's novel skin care, dark spot remover, TFC-1067, in a new clinical study. TFC-1067 will be tested using a new higher concentration (0.4%) and advanced formulation.
Oct 13, 2020 03:00 am ET
Sirona Biochem Signs Agreement with Global Pharmaceutical Company for Clinical Trial of its Novel Skincare Compound TFC-1067
VANCOUVER, BC, Oct. 13, 2020 /CNW/ - Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") is pleased to announce that it has signed an agreement with a top 10 global pharmaceutical company ("Company") to jointly test Sirona's novel skin care, dark spot remover, TFC-1067, in a new clinical study. TFC-1067 will be tested using a new higher concentration (0.4%) and advanced formulation.
Sep 09, 2020 09:00 am ET
/R E P E A T -- Sirona Biochem Contracts WuXi AppTec for Large-Scale Manufacturing of TFC-1067/
VANCOUVER, BC, Sept. 9, 2020 /CNW/ - Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") is pleased to announce it has signed an agreement with Contract Manufacturing Organization (CMO) WuXi AppTec ("WuXi"), Shanghai, to launch large-scale production of TFC-1067, a novel skin dark spot remover, for global commercialization.
Sep 09, 2020 03:00 am ET
Sirona Biochem Contracts WuXi AppTec for Large-Scale Manufacturing of TFC-1067
VANCOUVER, BC, Sept. 9, 2020 /CNW/ - Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") is pleased to announce it has signed an agreement with Contract Manufacturing Organization (CMO) WuXi AppTec ("WuXi"), Shanghai, to launch large-scale production of TFC-1067, a novel skin dark spot remover, for global commercialization.
Jun 16, 2020 09:00 am ET
/R E P E A T -- Sirona Biochem Ships First Batch of TFC-1067 to Rodan + Fields/
VANCOUVER, BC, June 16, 2020 /CNW/ - Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") is pleased to announce that it has made its first shipment of compound, TFC-1067, to industry leader Rodan + Fields, LLC ("Rodan + Fields") formulation team. Rodan + Fields will be the first to market for a consumer product utilizing TFC-1067 for the treatment of dyschromia (hyperpigmentation or "dark spots" of the skin).
Jun 16, 2020 03:00 am ET
Sirona Biochem Ships First Batch of TFC-1067 to Rodan + Fields
VANCOUVER, BC, June 16, 2020 /CNW/ - Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") is pleased to announce that it has made its first shipment of compound, TFC-1067, to industry leader Rodan + Fields, LLC ("Rodan + Fields") formulation team. Rodan + Fields will be the first to market for a consumer product utilizing TFC-1067 for the treatment of dyschromia (hyperpigmentation or "dark spots" of the skin).
Apr 14, 2020 09:00 am ET
/R E P E A T -- Sirona Biochem: Interview with Chief Scientific Officer Dr. Deliencourt-Godefroy on the Development Pipeline/
VANCOUVER, April 14, 2020 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") is pleased to inform its shareholders that a video interview with its Chief Scientific Officer, Dr. Géraldine Deliencourt-Godefroy, has been published by Austrian journalist Joachim Brunner (www.smallcapinvestor.de).
Apr 14, 2020 03:00 am ET
Sirona Biochem: Interview with Chief Scientific Officer Dr. Deliencourt-Godefroy on the Development Pipeline
VANCOUVER, April 14, 2020 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") is pleased to inform its shareholders that a video interview with its Chief Scientific Officer, Dr. Géraldine Deliencourt-Godefroy, has been published by Austrian journalist Joachim Brunner (www.smallcapinvestor.de).
Mar 31, 2020 09:00 am ET
/R E P E A T -- Sirona Biochem Initiates COVID-19 and Infectious Diseases Development Program/
VANCOUVER, March 31, 2020 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") is excited to announce its French subsidiary lab TFChem has initiated an antiviral program to produce potential new antiviral agents to assist in combating COVID-19 and other infectious diseases.
Mar 31, 2020 03:00 am ET
Sirona Biochem Initiates COVID-19 and Infectious Diseases Development Program
VANCOUVER, March 31, 2020 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") is excited to announce its French subsidiary lab TFChem has initiated an antiviral program to produce potential new antiviral agents to assist in combating COVID-19 and other infectious diseases.
Mar 18, 2020 09:00 am ET
/R E P E A T -- Sirona Biochem: Letter to the Shareholders/
VANCOUVER, March 18, 2020 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") is pleased to provide the following update:
Mar 18, 2020 03:00 am ET
Sirona Biochem: Letter to the Shareholders
VANCOUVER, March 18, 2020 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") is pleased to provide the following update:
Mar 04, 2020 08:00 am ET
/R E P E A T -- Sirona Biochem Signs Letter of Intent with Top Chinese Pharmaceutical Development Company/
Strategic Collaboration Planned to Bring Sirona's Product Pipeline to Commercial-Ready Stage
Mar 04, 2020 02:00 am ET
Sirona Biochem Signs Letter of Intent with Top Chinese Pharmaceutical Development Company
Strategic Collaboration Planned to Bring Sirona's Product Pipeline to Commercial-Ready Stage
Feb 14, 2020 06:00 pm ET
Sirona Biochem Announces Change of Auditor
VANCOUVER, Feb. 14, 2020 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC:SRBCF) (the "Company") announces that it has changed its auditors from MNP LLP (the "Former Auditor") to DeVisser Gray LLP (the "Successor Auditor") effective January 27, 2020 and the board of directors of the Company appointed the Successor Auditor as the Company's auditor effective January 27, 2020 until the next Annual General Meeting of the Company. There were no reservations in the Former Auditor's audit reports for the relevant period, being the financial years ended October 31, 2018 and October 31, 2
Jan 22, 2020 08:00 am ET
/R E P E A T -- Sirona Biochem: 100% Safety in Final Tox Study for Increased Concentration of TFC-1067/
VANCOUVER, Jan. 22, 2020 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") announces that the final toxicology test, a Human Repeated Insult Patch Test ("HRIPT"), has successfully been completed. Sirona is now in preparation for the increased dose (0.4%) clinical study for its skin lightening compound TFC-1067.
Jan 22, 2020 02:00 am ET
Sirona Biochem: 100% Safety in Final Tox Study for Increased Concentration of TFC-1067
VANCOUVER, Jan. 22, 2020 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") announces that the final toxicology test, a Human Repeated Insult Patch Test ("HRIPT"), has successfully been completed. Sirona is now in preparation for the increased dose (0.4%) clinical study for its skin lightening compound TFC-1067.
Jan 21, 2020 02:01 am ET
Sirona Biochem Announces Grant of Stock Options
VANCOUVER, Jan. 21, 2020 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB)(US-OTC: SRBCF)("Sirona" or the "Company") announces that it has granted an aggregate of 6,800,000 incentive stock options to management, independent directors and consultants of the Company. The options, to purchase common shares in the capital of the Company at a price of $0.45 per common share, will be for periods ranging from 1 to 10 years. The options have been granted under the terms of the Company's stock option plan.
Dec 19, 2019 08:00 am ET
/R E P E A T -- Sirona Biochem CEO Letter to Shareholders/
VANCOUVER, Dec. 19, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) ("Sirona") is pleased to provide the following update to shareholders.
Dec 19, 2019 02:00 am ET
Sirona Biochem CEO Letter to Shareholders
VANCOUVER, Dec. 19, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) ("Sirona") is pleased to provide the following update to shareholders.
Dec 02, 2019 08:00 am ET
/R E P E A T -- Sirona Biochem Reports 100% Safety in First Tox Study for Increased Concentration of TFC-1067/
VANCOUVER, Dec. 2, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") announces that the first toxicology test, in preparation for the new clinical study, has been completed with positive results.
Dec 02, 2019 02:00 am ET
Sirona Biochem Reports 100% Safety in First Tox Study for Increased Concentration of TFC-1067
VANCOUVER, Dec. 2, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") announces that the first toxicology test, in preparation for the new clinical study, has been completed with positive results.
Oct 30, 2019 09:00 am ET
/R E P E A T -- Sirona Biochem Proceeds to First Clinical Tests for Higher Concentrations to Increase Commercial Value of Skin Lightening Compound TFC-1067/
VANCOUVER, Oct. 30, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") is pleased to announce that testing of the higher concentration formulation of TFC-1067, first announced in June 2019, will proceed to Human Patch Test, followed by a Human Repeat Insult Patch Test (HRIPT).
Oct 30, 2019 03:00 am ET
Sirona Biochem Proceeds to First Clinical Tests for Higher Concentrations to Increase Commercial Value of Skin Lightening Compound TFC-1067
VANCOUVER, Oct. 30, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") is pleased to announce that testing of the higher concentration formulation of TFC-1067, first announced in June 2019, will proceed to Human Patch Test, followed by a Human Repeat Insult Patch Test (HRIPT).
Oct 23, 2019 09:00 am ET
/R E P E A T -- Sirona Biochem Hires Shanghai-based Chemistry Engineer to Select Local Manufacturer for Skin-Lightening Compound TFC-1067/
VANCOUVER, Oct. 23, 2019 /CNW/ - Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") is pleased to announce that it has engaged Mr. Pinqiao Zhao, an applied chemistry engineer from Shanghai, as a consultant to assist Sirona in selecting a manufacturer in China, and to communicate the necessary technical information for production of Sirona's innovative skin lightening compound TFC-1067.
Oct 23, 2019 03:00 am ET
Sirona Biochem Hires Shanghai-based Chemistry Engineer to Select Local Manufacturer for Skin-Lightening Compound TFC-1067
VANCOUVER, Oct. 23, 2019 /CNW/ - Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") is pleased to announce that it has engaged Mr. Pinqiao Zhao, an applied chemistry engineer from Shanghai, as a consultant to assist Sirona in selecting a manufacturer in China, and to communicate the necessary technical information for production of Sirona's innovative skin lightening compound TFC-1067.
Oct 15, 2019 07:58 am ET
Sirona Biochem: Agreement Signing Ceremony with Rodan + Fields at Cosmetic 360 Conference in Paris
VANCOUVER, Oct. 15, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") is pleased to announce that it will have a signing ceremony of its TFC-1067 License and Supply agreement with Rodan + Fields, LLC ("Rodan + Fields"). Rodan + Fields, the leading skin care brand in the United States1, is preparing to incorporate novel ingredient TFC-1067 into their product lines. Backed by extensive scientific research, TFC-1067 is clinically proven to be safe and effective at reducing the visibility of dark spots, brightening and evening skin tone.
Oct 09, 2019 09:00 am ET
/R E P E A T -- Sirona Biochem Signs Binding Term Sheet with Cosmetic Distributor in China/
VANCOUVER, Oct. 9, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") announces that it has completed a binding term sheet with Tinyi Trading Company ("Tinyi") for the distribution of its skin lightener TFC-1067 following strong commercial interest after clinical trial results. Tinyi will have distribution rights within Asia as well as exclusive rights for China.
Oct 09, 2019 03:00 am ET
Sirona Biochem Signs Binding Term Sheet with Cosmetic Distributor in China
VANCOUVER, Oct. 9, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") announces that it has completed a binding term sheet with Tinyi Trading Company ("Tinyi") for the distribution of its skin lightener TFC-1067 following strong commercial interest after clinical trial results. Tinyi will have distribution rights within Asia as well as exclusive rights for China.
Sep 25, 2019 09:00 am ET
/R E P E A T -- Sirona Biochem to Present Additional Clinical Results of TFC-1067 at Cosmetic 360 in Paris, France/
VANCOUVER, Sept. 25, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") announced that its Chief Scientific Officer, Dr. Geraldine Deliencourt-Godefroy, will represent Sirona at Cosmetic 360 in Paris, October 16-17, 2019. Since 2015, Cosmetic 360 has become an exclusive international event that allows the most influential cosmetic companies and industry decision makers to access the latest advancements in science.
Sep 25, 2019 03:00 am ET
Sirona Biochem to Present Additional Clinical Results of TFC-1067 at Cosmetic 360 in Paris, France
VANCOUVER, Sept. 25, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") announced that its Chief Scientific Officer, Dr. Geraldine Deliencourt-Godefroy, will represent Sirona at Cosmetic 360 in Paris, October 16-17, 2019. Since 2015, Cosmetic 360 has become an exclusive international event that allows the most influential cosmetic companies and industry decision makers to access the latest advancements in science.
Sep 18, 2019 09:00 am ET
/R E P E A T -- Sirona Biochem Signs Definitive License & Supply Agreement with Skincare Industry Leader Rodan + Fields/
VANCOUVER, Sept. 18, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) ("Sirona") is excited to announce that it has completed a definitive agreement with Rodan + Fields, LLC ("Rodan + Fields"), the leading skin care brand in the United States1, for the licensing and commercial sales of novel ingredient TFC-1067 to brighten and even skin tone. Rodan and Fields will be the first to market for a consumer product utilizing TFC-1067 in certain countries including United States.
Sep 11, 2019 09:00 am ET
Sirona Biochem Adopts Shareholder Rights Plan
VANCOUVER, Sept. 11, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") is pleased to announce that its board of directors has approved the adoption of a shareholder rights plan (the "Rights Plan"). The Rights Plan is subject to acceptance by the TSX Venture Exchange ("TSXV") and ratification by Sirona's shareholders within six months. If the shareholders do not ratify the Rights Plan at the AGM, the Rights Plan and all the rights outstanding at the time will terminate.
Jul 10, 2019 09:00 am ET
Sirona Biochem Announces Successful Close of Oversubscribed Private Placement
VANCOUVER, July 10, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (Frankfurt: ZSB) ("Sirona") is very pleased to announce today that it closed its private placement (Private Placement") as oversubscribed for gross proceeds of $1,500,000 CAD. The Private Placement consists of 3,750,000 units, (the "Units") at a price of $0.40 per Unit.  Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 3 years from the date of issue at a price of $0.60 per share subject to an accel
Jul 09, 2019 04:15 pm ET
Sirona Biochem Announces Proposed Strategic Equity Investment
Proceeds to be used for establishing Asia-based manufacturing for TFC-1067
Jul 04, 2019 09:00 am ET
/R E P E A T -- Sirona Biochem Releases CEO Letter to Shareholders/
VANCOUVER, July 4, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") is pleased to provide a corporate update from the Company's CEO, Dr. Howard Verrico, regarding its plans both near and long term in the following Q&A format. The questions, for the most part, are derived from inquiries received from investors:
Jul 04, 2019 03:01 am ET
Sirona Biochem Releases CEO Letter to Shareholders
VANCOUVER, July 4, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") is pleased to provide a corporate update from the Company's CEO, Dr. Howard Verrico, regarding its plans both near and long term in the following Q&A format. The questions, for the most part, are derived from inquiries received from investors:
Jul 03, 2019 09:00 am ET
/R E P E A T -- Sirona Biochem Announces SGLT2 Inhibitor Development Progress/
VANCOUVER, July 3, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") is pleased to announce that clinical development of Sirona's SGLT2 inhibitor, TFC-039, which is currently well into phase 1 of human trials, is progressing on schedule with no adverse events.
Jul 03, 2019 03:01 am ET
Sirona Biochem Announces SGLT2 Inhibitor Development Progress
VANCOUVER, July 3, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") is pleased to announce that clinical development of Sirona's SGLT2 inhibitor, TFC-039, which is currently well into phase 1 of human trials, is progressing on schedule with no adverse events.
Jun 20, 2019 02:02 pm ET
Sirona Biochem Reports 2019 AGM Voting and CEO Update
VANCOUVER, June 20, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) ("Sirona") is pleased to announce the voting results from its Annual General Meeting of Shareholders (the "Meeting"), held in Vancouver, British Columbia on June 20, 2019. The total number of shares represented by shareholders present in person and by proxy at the meeting was 32,141,666 million representing 15.47% of Sirona's issued and outstanding Common Shares.
Jun 19, 2019 09:00 am ET
/R E P E A T -- Sirona Biochem Signs Term Sheet for TFC-1067 with Skincare Industry Leader Rodan + Fields/
VANCOUVER, June 19, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) ("Sirona") is pleased to announce that a non-binding term sheet has been signed with Rodan + Fields, LLC (Rodan + Fields) for the commercial sales of novel ingredient TFC-1067. This term sheet covers all material terms and conditions of a definitive agreement with San Francisco-based, industry leading, Rodan + Fields. The definitive agreement is expected to be signed in Q3/2019.
Jun 19, 2019 03:01 am ET
Sirona Biochem Signs Term Sheet for TFC-1067 with Skincare Industry Leader Rodan + Fields
VANCOUVER, June 19, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) ("Sirona") is pleased to announce that a non-binding term sheet has been signed with Rodan + Fields, LLC (Rodan + Fields) for the commercial sales of novel ingredient TFC-1067. This term sheet covers all material terms and conditions of a definitive agreement with San Francisco-based, industry leading, Rodan + Fields. The definitive agreement is expected to be signed in Q3/2019.
Jun 17, 2019 09:00 am ET
/R E P E A T -- Sirona Biochem Announces TFC-1067 Skin Lightening Patent Granted in USA/
VANCOUVER, June 17, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) is pleased to announce that the patent for TFC-1067 entitled "Gem Difluorocompounds as Depigmenting or Lightening Agents" was granted in the USA, as expected, and will be published in the official database in the coming month. To date, the TFC-1067 skin lightening patent has been granted in Germany, France, United Kingdom and now the US. Further TFC-1067 patent applications are in the patent pending status in multiple other countries while they go through the normal approval process.
Jun 17, 2019 03:01 am ET
Sirona Biochem Announces TFC-1067 Skin Lightening Patent Granted in USA
VANCOUVER, June 17, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) is pleased to announce that the patent for TFC-1067 entitled "Gem Difluorocompounds as Depigmenting or Lightening Agents" was granted in the USA, as expected, and will be published in the official database in the coming month. To date, the TFC-1067 skin lightening patent has been granted in Germany, France, United Kingdom and now the US. Further TFC-1067 patent applications are in the patent pending status in multiple other countries while they go through the normal approval process.
Jun 12, 2019 08:00 am ET
Sirona Biochem Appoints Chinese Lawyer Jason Tian to its Board of Directors
VANCOUVER, June 12, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the "Company") announces that Mr. Jason Tian will be joining its Board of Directors. Jason Tian is a Senior Partner at Landing Law offices based in Shanghai, China. Jason has been working with Sirona since 2018 representing the Company at strategic partnering meetings in China and France.
Jun 11, 2019 09:00 am ET
/R E P E A T -- Sirona Biochem Reports Approval to Test Higher Concentrations of Skin Lightening Compound TFC-1067/
VANCOUVER, June 11, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") is pleased to announce that it will assess its novel skin lightener, TFC-1067, at a concentration 3 times higher than what was used in the previous clinical trial. Higher dosing is expected to have increased efficacy, but also the potential to work more quickly than the clinically effective dose established for TFC-1067. This positive development is of substantial commercial interest to potential cosmetic partners in North America and China who share Sirona's goal to maximize efficacy without compromisin
Jun 11, 2019 03:01 am ET
Sirona Biochem Reports Approval to Test Higher Concentrations of Skin Lightening Compound TFC-1067
VANCOUVER, June 11, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") is pleased to announce that it will assess its novel skin lightener, TFC-1067, at a concentration 3 times higher than what was used in the previous clinical trial. Higher dosing is expected to have increased efficacy, but also the potential to work more quickly than the clinically effective dose established for TFC-1067. This positive development is of substantial commercial interest to potential cosmetic partners in North America and China who share Sirona's goal to maximize efficacy without compromisin
May 28, 2019 09:00 am ET
/R E P E A T -- Sirona Biochem Reports Excellent Preliminary Safety Assessment of Lead Anti-Wrinkle Compound LIP-01/
VANCOUVER, May 28, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") is pleased to announce safety testing on its lead glycoprotein compound in the anti-wrinkle program yielded excellent results and the company will immediately move to the next steps of development. This project was generously supported by BPI France and the region Haute Normandie.
May 28, 2019 03:01 am ET
Sirona Biochem Reports Excellent Preliminary Safety Assessment of Lead Anti-Wrinkle Compound LIP-01
VANCOUVER, May 28, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") is pleased to announce safety testing on its lead glycoprotein compound in the anti-wrinkle program yielded excellent results and the company will immediately move to the next steps of development. This project was generously supported by BPI France and the region Haute Normandie.
May 22, 2019 09:00 am ET
/R E P E A T -- Sirona Biochem Hires Contract Research Organization for Manufacturing Process Optimization for TFC-1067/
VANCOUVER, May 22, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") is pleased to announce it has commissioned Contract Research Organization (CRO) Roowin (www.roowin.com) to develop the final chemical process required for large scale manufacturing of TFC-1067. This is another important step in the commercialization of Sirona's novel skin lightening agent.
May 22, 2019 03:01 am ET
Sirona Biochem Hires Contract Research Organization for Manufacturing Process Optimization for TFC-1067
VANCOUVER, May 22, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") is pleased to announce it has commissioned Contract Research Organization (CRO) Roowin (www.roowin.com) to develop the final chemical process required for large scale manufacturing of TFC-1067. This is another important step in the commercialization of Sirona's novel skin lightening agent.
May 15, 2019 09:00 am ET
/R E P E A T -- Sirona Biochem Receives Positive Clinical Results of its Skin Lightening Compound TFC-1067 from China/
VANCOUVER, May 15, 2019 /CNW/ - Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) ("Sirona") is pleased to announce results of a clinical trial performed in the Peoples Republic of China (China) using Sirona's novel skin lightening agent TFC-1067. Sirona's TFC-1067 once again demonstrated significant clinical lightening effect without any reported adverse effects.
May 15, 2019 03:01 am ET
Sirona Biochem Receives Positive Clinical Results of its Skin Lightening Compound TFC-1067 from China
VANCOUVER, May 15, 2019 /CNW/ - Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) ("Sirona") is pleased to announce results of a clinical trial performed in the Peoples Republic of China (China) using Sirona's novel skin lightening agent TFC-1067. Sirona's TFC-1067 once again demonstrated significant clinical lightening effect without any reported adverse effects.
Apr 10, 2019 09:00 am ET
/R E P E A T -- Sirona Biochem's TFC-1067 Demonstrates Superiority to Hydroquinone for the Treatment of Dyschromia/
VANCOUVER, April 10, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the "Company") is pleased to announce the results of its clinical trial performed by Dr. Zoe Draelos of Dermatology Consulting Services, conducted in North Carolina, USA. Sirona's TFC-1067 demonstrates superiority to the gold standard, hydroquinone, for the treatment of dyschromia (hyperpigmentation or "dark spots" of the skin).
Apr 10, 2019 03:01 am ET
Sirona Biochem's TFC-1067 Demonstrates Superiority to Hydroquinone for the Treatment of Dyschromia
VANCOUVER, April 10, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the "Company") is pleased to announce the results of its clinical trial performed by Dr. Zoe Draelos of Dermatology Consulting Services, conducted in North Carolina, USA. Sirona's TFC-1067 demonstrates superiority to the gold standard, hydroquinone, for the treatment of dyschromia (hyperpigmentation or "dark spots" of the skin).
Feb 27, 2019 10:40 am ET
Sirona Biochem Announces Close of Oversubscribed Private Placement
VANCOUVER, Feb. 27, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (Frankfurt: ZSB) (Xetra: ZSB) (the "Company") announced today that it has closed an oversubscribed, non-brokered private placement for gross proceeds of $1,783,500. The private placement consists of 17,835,000 units, (the "Units") at a price of $0.10 per Unit.  Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant is exercisable into one additional common share of the Company for a period of 3 years from the date of issue at a price of $0.16 per share.
Feb 26, 2019 08:00 am ET
/R E P E A T -- Sirona Biochem to Exhibit at PCHi 2019 in Guanzhou China/
VANCOUVER, Feb. 26, 2019 /CNW/ -  Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the "Company") announces that it will exhibit at The Personal Care and Homecare Ingredients trade show (PCHi 2019) in Guanzhou China Feb 26-28th 2019. The PCHi 2019 trade show is China's #1 sourcing platform for the global personal care industry  https://www.pchi-china.com/en/. Sirona will be principally promoting its novel skin lightening agent TFC-1067 in addition to its anti-wrinkle and anti-aging compounds.
Feb 26, 2019 02:01 am ET
Sirona Biochem to Exhibit at PCHi 2019 in Guanzhou China
VANCOUVER, Feb. 26, 2019 /CNW/ -  Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the "Company") announces that it will exhibit at The Personal Care and Homecare Ingredients trade show (PCHi 2019) in Guanzhou China Feb 26-28th 2019. The PCHi 2019 trade show is China's #1 sourcing platform for the global personal care industry  https://www.pchi-china.com/en/. Sirona will be principally promoting its novel skin lightening agent TFC-1067 in addition to its anti-wrinkle and anti-aging compounds.
Feb 15, 2019 04:00 pm ET
Sirona Biochem Announces Financing
VANCOUVER, Feb. 15, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (Frankfurt: ZSB) the "Company") announced today that it has arranged a non-brokered private placement for gross proceeds of $1,000,000. The private placement consists of 10,000,000 units, (the "Units") at a price of $0.10 per Unit.  Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 3 years from the date of issue at a price of $0.16 per share.
Feb 13, 2019 08:00 am ET
/R E P E A T -- Sirona Biochem Advances Skin Lightener TFC-1067 Development and IP Protection in Anticipation of Licensing Discussions/
VANCOUVER, Feb. 13, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the "Company") announces that it has advanced the commercial development and IP protection of its novel skin lightening agent TFC-1067.
Feb 13, 2019 02:01 am ET
Sirona Biochem Advances Skin Lightener TFC-1067 Development and IP Protection in Anticipation of Licensing Discussions
VANCOUVER, Feb. 13, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the "Company") announces that it has advanced the commercial development and IP protection of its novel skin lightening agent TFC-1067.
Feb 06, 2019 08:00 am ET
/R E P E A T -- Sirona Biochem Receives Up-front Payment for Right of First Refusal Contract for Skin Lightener TFC-1067/
VANCOUVER, Feb. 6, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the "Company") announces that it has signed a Right of First Refusal (ROFR) agreement with an industry-leading, skincare company to license Sirona's skin lightener, TFC-1067. The company is a leader in North American skincare sales with rapidly growing international sales channels.
Feb 06, 2019 02:01 am ET
Sirona Biochem Receives Up-front Payment for Right of First Refusal Contract for Skin Lightener TFC-1067
VANCOUVER, Feb. 6, 2019 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the "Company") announces that it has signed a Right of First Refusal (ROFR) agreement with an industry-leading, skincare company to license Sirona's skin lightener, TFC-1067. The company is a leader in North American skincare sales with rapidly growing international sales channels.
Jan 30, 2019 08:00 am ET
Jan 30, 2019 02:01 am ET
Sirona Biochem releases CEO Letter to Shareholders
Clinical trial results expected Q1 2019
Dec 11, 2018 07:00 am ET
Sirona Biochem's SGLT2 Inhibitor in Testing for Animal Health
VANCOUVER, Dec. 11, 2018 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the "Company") announced today that testing has commenced for the SGLT2 inhibitor, TFC-039, in cats.
Nov 06, 2018 07:00 am ET
Sirona Biochem Begins Proof of Efficacy Clinical Trial for TFC-1067
VANCOUVER, Nov. 6, 2018 /CNW/ - Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the "Company") reported today the successful launch of the clinical trial for skin-lightener TFC-1067 with leading dermatologist Dr. Zoe Draelos.
Oct 17, 2018 08:00 am ET
Sirona Biochem Engages Consultant for Japanese Market Penetration
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (Xetra: ZSB) (the “Company”) is pleased to announce that it has engaged Mr. Sven Harpering, a Tokyo-based consultant, with the help of its strategic advisory firm, PRC Partners (“PRC”) to fast-track...
Oct 16, 2018 06:00 pm ET
Sirona Biochem Announces Close of Financing and Extension of Convertible Notes
Sirona Biochem Corp. (TSX-V: SBM) (Frankfurt: ZSB) (the “Company”) announced that it has closed a private placement (subject to TSX.V approval) in the amount of 7,095,100 units at $0.10 per unit for total gross proceeds of $709,510. Each unit...
Oct 11, 2018 08:00 am ET
Sirona Biochem to Present at the 2018 Arctic Circle Assembly
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the “Company”) announced today that Chief Scientific Officer, Dr. Geraldine Deliencourt-Godefroy will attend and present at the Arctic Circle Assembly. This conference will take place October 19th –...
Sep 28, 2018 08:00 am ET
Sirona Biochem CEO’s Report on Progress
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (Xetra: ZSB) (the “Company”) provided a shareholder corporate update today from the Company’s CEO, Dr. Howard J Verrico. Dear Shareholders, As the summer comes to a close and we enter the final months...
Sep 26, 2018 08:00 am ET
Sirona Biochem Receives Positive Safety Data for Lead Skin-Lightener in Preparation for Clinical Trial in the US
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (Xetra: ZSB) (the “Company”) is pleased to report further progress regarding the clinical development of its lead skin-lightener, TFC-1067. In parallel with ongoing partnering discussions, Sirona has...
Aug 28, 2018 08:00 am ET
Sirona Biochem Receives $500,000 USD Milestone Payment from Wanbang Biopharmaceuticals
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (Xetra: ZSB) (the “Company”) announced that it has received the $500,000 USD milestone payment from partner Wanbang Biopharmaceuticals Co., Ltd (“Wanbang”) for approval by the China Food and Drug...
Jul 12, 2018 08:00 am ET
Sirona Biochem Announces CFDA Approval of SGLT2 Inhibitor for Phase I Clinical Trial
Sirona Biochem Corp. (TSX-V:SBM) (FSE:ZSB) (the “Company”) announced today that partner, Jiangsu Wanbang Biopharmaceuticals (“Wanbang”), has confirmed the Investigational New Drug (IND) submission to China’s Food and Drug Administration (CFDA) for...
May 14, 2018 10:19 pm ET
Sirona Biochem Receives TSX Venture Exchange Approval on Warrant Extension
Sirona Biochem Corp. (TSX-V:SBM) (FRANKFURT:ZSB), announces an extension to the term of 2,073,750 common share purchase warrants (the “Warrants”) originally issued on May 11, 2016. The warrants were issued as part of a private placement. The expiry...
Apr 30, 2018 08:00 am ET
Sirona Biochem to Exhibit at the Shanghai China Beauty Expo 2018
VANCOUVER, British Columbia, April 30, 2018 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V:SBM) (FSE:ZSB) (the “Company”) announced today that they will be exhibitors at China Beauty Expo (CBE) 2018. The trade show will be held May 22-24 in...
Feb 02, 2018 02:53 pm ET
Sirona Biochem Announces Chief Scientific Officer to Present at Adaptations in Polar Environments and Biomimicry
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") announced today that Chief Scientific Officer, Dr. Geraldine Deliencourt-Godefroy will attend and present at the Paris symposium: Adaptations in Polar Environments...
Jan 31, 2018 08:00 am ET
Sirona Biochem Announces Development of Anti-Wrinkle Treatment and Update from J.P. Morgan Healthcare Conference
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") announced today that the Company is developing an anti-wrinkle therapy. The compound, LIP-01, was discovered to have a novel mechanism of action and will enter...
Jan 29, 2018 08:00 am ET
Sirona Biochem Announces Receipt of $500,000 US Milestone Payment
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") is pleased to announce that the $500,000 USD payment from Wanbang Biopharmaceuticals has been received. The Company now awaits the China Food and Drug...
Dec 29, 2017 08:00 am ET
Sirona Biochem Announces SGLT2 IND Submission Milestone
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") announced today that partner Jiangsu Wanbang Biopharmaceuticals has confirmed an Investigational New Drug (IND) submission to China's Food and Drug Administration...
Dec 19, 2017 04:00 pm ET
Sirona Biochem Announces Results of AGM & CEO Update
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") announces that all resolutions tabled at its Annual General Meeting held on December 18, 2017, were passed. The resolutions included:Fixing the number of directors...
Nov 20, 2017 05:38 pm ET
Sirona Biochem Announces Grant of Stock Options
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") announces that it has granted an aggregate of 2,350,000 bonus and incentive stock options to management, independent directors and consultants of the Company. The...
Oct 27, 2017 07:00 pm ET
Sirona Biochem Announces Resignation of Board Director
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) announced today the resignation of Mr. David Moore from the board of directors due to conflicting commitments. "We are very thankful to Mr. Moore for his contributions and...
Oct 26, 2017 01:34 pm ET
Sirona Biochem Announces Close of Oversubscribed Private Placement
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") announced today that it has closed an oversubscribed, non-brokered private placement for gross proceeds of $635,000. The private placement consists of 4,233,333...
Oct 24, 2017 09:04 pm ET
Sirona Biochem Announces Financing
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") announced today that it has arranged a non-brokered private placement for gross proceeds of $535,000. The private placement consists of 3,566,667 units, (the...
Oct 16, 2017 08:00 am ET
Sirona Biochem to Present Kel-01 at Cosmetic 360 in Paris, France
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB), (the "Company") announced that Chief Scientific Officer, Dr. Geraldine Deliencourt-Godefroy, will attend and present on the trade floor at Cosmetic 360 in Paris, France on...
Sep 27, 2017 08:00 am ET
Sirona Subsidiary, TFChem, Receives Final Loan Tranche from French Public Investment Bank for Anti-Aging Project
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB), (the "Company") announced that its wholly-owned French subsidiary, TFChem, has received the final tranche of the CDN$1.2 million from Bpifrance (the French Public Investment...
Sep 21, 2017 08:00 am ET
Sirona Biochem CEO's Report on Progress
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) is pleased to provide a corporate update. Dear Shareholders,I would like to thank you for your continued support while we work through the negotiations for our skin lightener. The following is...
Sep 13, 2017 04:16 pm ET
Sirona Biochem Announces Resignation of Board Director
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) announced today the resignation of Dr. Martin Gleave from the board of directors. Dr. Gleave is involved in a new venture that could result in a potential conflict. Accordingly...
Aug 23, 2017 06:06 pm ET
Sirona Biochem Receives TSX Venture Exchange Approval on Warrant Extension
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB), announces an extension to the term of 8,850,770 common share purchase warrants (the "Warrants") originally issued on March 6, 2014. The warrants were issued as part of a private placement....
Jul 06, 2017 08:00 am ET
Sirona Biochem Announces Positive Efficacy Results for Skin Lightening Library
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") announced positive preclinical efficacy data for its library of skin lightening compounds. The study was conducted at Bioalternatives in France, a contract...
Jun 05, 2017 04:18 pm ET
Sirona Biochem Closes Convertible Note Financing
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) is pleased to announce that it has closed the non-brokered private placement (the "Private Placement") of convertible notes ("Notes"). The financing was oversubscribed, resulting...
May 31, 2017 08:00 am ET
Sirona Biochem Announces Convertible Note Financing
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) announced today a non-brokered private placement (the "Private Placement") of convertible notes ("Notes") for gross proceeds of up to $500,000. Each Note will be convertible at...
Apr 20, 2017 04:22 pm ET
Sirona Biochem Receives TSX Venture Exchange Approval on Warrant Extension
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) announces an extension to the term of 8,850,770 common share purchase warrants (the "Warrants") originally issued on March 6, 2014. The warrants were issued as part of a private...
Apr 05, 2017 08:00 am ET
Sirona Biochem Announces Keloid Data Accepted for Presentation to the Society of Investigative Dermatology (SID)
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") announced today that it has been accepted to present recent data at the 76th Annual Society of Investigative Dermatology (SID) Meeting, April 26-29 in Portland,...
Feb 16, 2017 06:57 pm ET
Sirona Biochem Announces Management Changes
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) announces that the Company has terminated Attila Hajdu's employment by mutual agreement. The Company is pleased to announce the addition of Aleksandra Kasikovic to its team in a...
Feb 03, 2017 04:43 pm ET
Sirona Biochem Closes Convertible Note Financing
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) is pleased to announce that it has closed the non-brokered private placement (the "Private Placement") of convertible notes ("Notes"). The financing was oversubscribed, resulting...
Jan 31, 2017 06:33 pm ET
Sirona Biochem Announces Convertible Note Financing
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) announced today a non-brokered private placement (the "Private Placement") of convertible notes ("Notes") for gross proceeds of up to $600,000. Each Note will be convertible at...
Dec 08, 2016 08:00 am ET
Sirona Biochem CEO's Report on Progress
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) today provided a business update. Dear Shareholders,The following is an update on our progress in 2016 and our plans for 2017.Skin Lightener, TFC-1067Throughout 2016, we have...
Oct 25, 2016 05:30 pm ET
Sirona Biochem CEO to Present at French Consulate and Business in France Roundtable Event
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") is pleased to announce that CEO, Dr. Howard Verrico, has been invited by the Consulate of France in Vancouver and Business in France to present at a roundtable...
Sep 22, 2016 05:33 pm ET
Sirona Biochem -- Results of Annual General Meeting
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") announces that all resolutions tabled at its Annual General Meeting held on September 21, 2016, were passed. The resolutions included:Fixing the number of...
Jun 30, 2016 08:00 am ET
Sirona Biochem CEO's Report on Progress
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) today provided a business update.Dear Shareholders,I would like to provide an update on our progress.As we enter Q3, our resources continue to be focused on completing a license...
Jun 22, 2016 08:41 pm ET
Sirona Biochem Announces Grant of Stock Options
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") announces that it has granted an aggregate of 400,000 incentive stock options to independent directors of the Company to purchase up to a total of 400,000 common...
Jun 16, 2016 08:00 am ET
Sirona Biochem Announces Positive Safety and Efficacy Data for Innovative Skin Lightening Compound SBM-TFC-1067 Accepted as Abstract Presentation by IMCAS
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") announced positive preclinical safety and efficacy data with SBM-TFC-1067 in a 3-D human skin-like model was accepted as an abstract for oral presentation by...
Jun 13, 2016 08:00 am ET
Sirona Biochem Announces Wanbang Biopharmaceuticals to Proceed to Pre-IND Testing and Receipt of $300,000 USD Milestone Payment
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") today announced that Wanbang Biopharmaceuticals has confirmed they will be proceeding with studies to prepare for Investigational New Drug (IND) filing for the...
May 17, 2016 08:00 am ET
Sirona Biochem to Present New Test Results of SBM-TFC-1067 at Global Conferences
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") is pleased to announce participation, in the form of presentations and exhibitions, in several global cosmetic industry conferences."Maintaining a strong presence...
May 11, 2016 09:01 pm ET
Sirona Biochem Announces Close of Financing
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") is pleased to announce that it has closed a private placement in the amount of 4,147,500 units at $0.20 per unit for total gross proceeds of $829,500. Each unit...
Apr 18, 2016 08:00 am ET
Sirona Biochem Initiates Research and Development on New Therapies for Keloid Scars and Acne Vulgar
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") announces that its CEO, Dr. Howard Verrico, has approved two new therapeutic projects within the skin care portfolio addressing markets with unmet needs. Research...
Apr 11, 2016 08:00 am ET
Sirona Biochem Begins Cell Preservation Research Collaboration With Dr. Caigan Du, University of British Columbia
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") announces that it has entered into a research collaboration with Dr. Caigan Du of the University of British Columbia to study the effects of new compounds,...
Mar 21, 2016 08:00 am ET
Sirona Biochem Selected to Present at BIO-Europe Spring
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the "Company") announces that its Chief Business Development Officer, Attila Hajdu, will be presenting at BIO-Europe Spring on April 4, 2016, at 10:00 AM CET at the Kistamässan...
Jan 25, 2016 08:00 am ET
Sirona Biochem Invited to Present at Dose of the Valley Conference, San Francisco
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) announces that it has been chosen for a second time, by the Consulate General of Canada, to present at the Dose of the Valley conference on February 9 - 10 in San Francisco,...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.